Grundläggande statistik
| CIK | 1036968 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Diadexus, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| April 29, 2016 |
Diadexus 10-Q (Quarterly Report) ddxs-10q20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-26483 Diadexus, Inc. (Exact nam |
|
| April 29, 2016 |
EX-10.3 4 ddxs-ex1039.htm EX-10.3 Exhibit 10.3 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. License and Supply Agreement This License and Supply Agreement (the “Agreement”) is made and entered into by |
|
| April 29, 2016 |
DIADEXUS, INC. KEY EMPLOYEE SEVERANCE BENEFIT PLAN (as amended, July 15, 2015) Exhibit 10.1 DIADEXUS, INC. KEY EMPLOYEE SEVERANCE BENEFIT PLAN (as amended, July 15, 2015) 1.Introduction. The Compensation Committee of the Board of Directors of Diadexus, Inc. (the “Company”) first approved this Key Employee Severance Benefit Plan (the “Plan”) on October 30, 2013, and amended this Plan on December 15, 2014 and July 15, 2015. The Plan provides for severance benefits to selected |
|
| April 29, 2016 |
diaDexus, Inc. Non-Employee Director Compensation Policy EX-10.2 3 ddxs-ex1027.htm EX-10.2 Exhibit 10.2 diaDexus, Inc. Non-Employee Director Compensation Policy Approved: July 15, 2015 (the “Adoption Date”) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of diaDexus, Inc. (the “Company”) or any of its subsidiaries (each such non-employee member, a “Director”) will receive the following compensation for his or h |
|
| April 28, 2016 |
Exhibit 99.1 Diadexus, Inc. Reports First Quarter 2016 Financial Results - PLAC® Activity Test Launch Broadens as FDA-Cleared Test for Coronary Heart Disease Risk Assessment Now Available Nationally - SOUTH SAN FRANCISCO, Calif., April 28, 2016 - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today ann |
|
| April 28, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ddxs-8k20160428.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2016 Diadexus, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 18, 2016 |
Diadexus, Inc. Previews First Quarter 2016 Financial Performance and Provides Business Update ddxs-ex9917.htm Exhibit 99.1 Diadexus, Inc. Previews First Quarter 2016 Financial Performance and Provides Business Update SOUTH SAN FRANCISCO, Calif., April 18, 2016 - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced preliminary financial performance metrics for the first quarter ended M |
|
| April 18, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ddxs-8k20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2016 Diadexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Co |
|
| April 1, 2016 |
ddxs-ex1634.htm Exhibit 16.1 April 1, 2016 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Diadexus, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of Diadexus, Inc. dated March 31, 2016. We agree with the sta |
|
| April 1, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant ddxs-8k20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 Diadexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 29, 2016 |
ddxs-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-26483 Diadexus, Inc. (Exact name of Registrant |
|
| March 29, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ddxs-8k20160328.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2016 Diadexus, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 29, 2016 |
5 DIADEXUS, INC. CONDENSED STATEMENTS OF OPERATIONS (In thousands, except share data) ddxs-ex9916.htm Exhibit 99.1 Updated - Diadexus, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results SOUTH SAN FRANCISCO, CA - (Marketwired) - 03/28/16 - Diadexus, Inc. (OTCQB: DDXS) - The enclosed Condensed Statements of Operations and the Condensed Balance Sheets are updated for appropriate classification of three line items. Diadexus, Inc. Reports Fourth Quarter and Full Year 2015 |
|
| March 28, 2016 |
JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.1 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Diadexus, Inc., a Delaware corporation (the “Company”); WHEREAS, (i) Meson Capital, LP, Meson Capital Partners LLC and Ryan J. Morris (“RJM”) (collectively, the “Meson Stockholders”), (ii) The Evans Drive Trust, Brian J. Roach (“BJR”), Wendy E. Reisman and Margaret P. |
|
| March 28, 2016 |
DDXS / Diadexus, Inc. / Meson Capital Partners LLC - THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Diadexus, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 25245P 20 5 (CUSIP Number) RYAN J. MORRIS MESON CAPITAL PAR |
|
| March 28, 2016 |
Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Brian J. Roach, the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of Diadexus, Inc. (the “Company”) directly or indirectly beneficially ow |
|
| March 17, 2016 |
ddxs-8k20160314.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2016 Diadexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 9, 2016 |
DDXS / Diadexus, Inc. / GLAXOSMITHKLINE PLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DIADEXUS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 25245P 20 5 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| October 26, 2015 |
Diadexus 8-K (Current Report/Significant Event) ddxs-8k20150930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2015 Diadexus, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 26, 2015 |
EX-99.1 2 ddxs-ex9916.htm EX-99.1 Exhibit 99.1 Diadexus, Inc. Reports Third Quarter 2015 Financial Results - New Commercial Team in Place and Gaining Sales Traction for PLAC® Activity in the Hospital Channel – - Stable PLAC® ELISA Business – SOUTH SAN FRANCISCO, Calif., October 26, 2015 - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the pr |
|
| September 8, 2015 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2015 Diadexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of I |
|
| August 21, 2015 |
ddxs-8k20150820.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2015 Diadexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (C |
|
| August 13, 2015 |
ddxs-ex9918.htm Exhibit 99.1 Diadexus, Inc. Reports Second Quarter 2015 Financial Results - Conference Call Today at 4:30 p.m. ET (1:30 p.m. PT) - SOUTH SAN FRANCISCO, Calif., August 13, 2015 - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the six months and quart |
|
| August 13, 2015 |
Diadexus 8-K (Current Report/Significant Event) ddxs-8k20150813.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2015 Diadexus, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 2, 2015 |
Diadexus 8-K (Current Report/Significant Event) ddxs-8k20150630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2015 Diadexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 1, 2015 |
Diadexus 8-K (Current Report/Significant Event) ddxs-8k20150630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2015 Diadexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 1, 2015 |
CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION diaDexus, Inc. EX-3.1 2 ddxs-ex31201506306.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF diaDexus, Inc. diaDexus, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies that: FIRST:The name of the Corporation is diaDexus, Inc. The Corporation was originally incor |
|
| June 17, 2015 |
POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby authorizes Lori F. |
|
| June 10, 2015 |
Submission of Matters to a Vote of Security Holders ddxs-8k20150609.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2015 diaDexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 13, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2015 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of Incorp |
|
| May 13, 2015 |
EX-99.1 Exhibit 99.1 Diadexus, Inc. Reports First Quarter 2015 Financial Results ? Conference Call Today at 4:30 p.m. ET (1:30 p.m. PT) ? SOUTH SAN FRANCISCO, Calif., May 12, 2015 ? Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the first quarter ended March 31, 20 |
|
| April 30, 2015 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 30, 2015 |
Diadexus DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| April 22, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2015 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of Incorporati |
|
| April 22, 2015 |
Lori Rafield, Ph.D. Appointed Permanent CEO of Diadexus EX-99.1 Exhibit 99.1 Lori Rafield, Ph.D. Appointed Permanent CEO of Diadexus SOUTH SAN FRANCISCO, Calif., April 20, 2015 - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced the appointment of Lori F. Rafield, Ph.D. as chief executive officer of the Company on a permanent basis, effective i |
|
| April 20, 2015 |
Diadexus PRELIMINARY PROXY STATEMENT Preliminary Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 20, 2015 |
EX-99.1 2 ex991to13da307617007041615.htm AGREEMENT, DATED APRIL 16, 2015 Exhibit 99.1 AGREEMENT This agreement, effective April 16, 2015 (this “Agreement”), is made by and among Leap Tide Capital Management, LLC, and Jan Loeb (each, a “Leap Tide Stockholder,” and collectively, the “Leap Tide Group”), and DiaDEXUS, Inc. (“DiaDEXUS” or the “Company”). In consideration of and in reliance upon the mut |
|
| April 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 diaDexus, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 25245P106 (CUSIP Number) JAN H. LOEB LEAP TIDE C |
|
| April 20, 2015 |
Diadexus 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2015 diaDexus, Inc. |
|
| April 20, 2015 |
EX-10.1 Exhibit 10.1 AGREEMENT This agreement, effective April 16, 2015 (this ?Agreement?), is made by and among LEAP TIDE CAPITAL MANAGEMENT, LLC, and JAN LOEB (each, a ?Leap Tide Stockholder,? and collectively, the ?Leap Tide Group?), and DIADEXUS, INC. (?DiaDEXUS? or the ?Company?). In consideration of and in reliance upon the mutual covenants and agreements contained herein, and for other good |
|
| March 12, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2015 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction (IRS Employe |
|
| March 12, 2015 |
EX-99.1 2 d887652dex991.htm EX-99.1 Exhibit 99.1 Diadexus, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results — Total Revenue of $26.4 Million for Full Year 2014, 6% Increase — — New FDA-Cleared PLAC® Test for Lp-PLA2 Activity Launch Underway — — Conference Call Today at 4:30 p.m. ET (1:30 p.m. PT) — SOUTH SAN FRANCISCO, Calif., March 11, 2015 — Diadexus, Inc. (OTCQB: DDXS), a diagno |
|
| March 10, 2015 |
diaDexus, Inc. Announces Appointment of Leone Patterson as Chief Financial Officer EX-99.1 2 d889288dex991.htm EX-99.1 Exhibit 99.1 diaDexus, Inc. Announces Appointment of Leone Patterson as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., March 2, 2015 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced the appointment of Leone Patterson as chief financial officer. “We are fortunate to have |
|
| March 10, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2015 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of Incor |
|
| March 2, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2015 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of Incorp |
|
| March 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 diaDexus, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 25245P106 (CUSIP Number) JAN H. LOEB LEAP TIDE C |
|
| March 2, 2015 |
diaDexus, Inc. Announces Appointment of John Curnutte, M.D., Ph.D. to its Board of Directors EX-99.1 Exhibit 99.1 For Release: February 24 at 1:00 pm PT diaDexus, Inc. Announces Appointment of John Curnutte, M.D., Ph.D. to its Board of Directors SOUTH SAN FRANCISCO, Calif., February 24, 2015 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced the appointment of John Curnutte, M.D., Ph.D. as an independent |
|
| February 11, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2015 diaDexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 8, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2015 diaDexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 8, 2015 |
diaDexus, Inc. Announces Appointment of James Sulat and Elizabeth Hutt to its Board of Directors EX-99.1 Exhibit 99.1 For Release: January 7 at 1:00 pm PT diaDexus, Inc. Announces Appointment of James Sulat and Elizabeth Hutt to its Board of Directors SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced the appointment of James Sulat and Elizabeth Hutt as members o |
|
| January 8, 2015 |
SC 13D/A 1 formsc13da.htm NORMAN H. PESSIN SC 13DA NO 2 1-8-2015 (DIADEXUS, INC) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Diadexus, Inc. (Name of Issuer) Common Stock, $.01 Par Value (Title of Class of Securities) 25245P 10 6 Cusip Number Norman H. Pessin Brian Pessin 366 Madison Avenue, 14th |
|
| January 6, 2015 |
diaDexus, Inc. Updates on 2014 Achievements and 2015 Initiatives EX-99.1 Exhibit 99.1 For Release: January 5 at 1:00 pm PT diaDexus, Inc. Updates on 2014 Achievements and 2015 Initiatives SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today highlighted recent achievements and provided an outlook for its business and initiatives in 2015. “Our p |
|
| January 6, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2015 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of Incorpor |
|
| December 30, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2014 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of Incorp |
|
| December 19, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2014 DIADEXUS, INC. |
|
| December 19, 2014 |
DIADEXUS, INC. KEY EMPLOYEE SEVERANCE BENEFIT PLAN (as amended, December 15, 2014) EX-10.1 Exhibit 10.1 DIADEXUS, INC. KEY EMPLOYEE SEVERANCE BENEFIT PLAN (as amended, December 15, 2014) 1. Introduction. The Compensation Committee of the Board of Directors of diaDexus, Inc. (the “Company”) first approved this Key Employee Severance Benefit Plan (the “Plan”) on October 30, 2013, and amended this Plan on December 15, 2014. The Plan provides for severance benefits to selected emplo |
|
| December 15, 2014 |
DDXS / Diadexus, Inc. / LEAP TIDE CAPITAL MANAGEMENT, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 diaDexus, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 25245P106 (CUSIP Number) JAN H. LOEB LEAP TIDE C |
|
| November 5, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2014 diaDexus, Inc. |
|
| November 5, 2014 |
Exhibit 99.1 diaDexus, Inc. Reports Third Quarter 2014 Financial Results - Conference Call Today at 4:30 p.m. ET (1:30 p.m. PT) - SOUTH SAN FRANCISCO, Calif. - (BUSINESS WIRE) - diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the third quarter ended September 30, 2014. “We remain focused on |
|
| October 27, 2014 |
EX-99.1 2 ex991to13d0761700710132014.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.01 par v |
|
| October 27, 2014 |
DDXS / Diadexus, Inc. / LEAP TIDE CAPITAL MANAGEMENT, LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 diaDexus, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 25245P106 (CUSIP Number) JAN H. LOEB LEAP TIDE CA |
|
| October 20, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Diadexus, Inc. (Name of Issuer) Common Stock, $.01 Par Value (Title of Class of Securities) 25245P 10 6 Cusip Number Norman H. Pessin Brian Pessin 366 Madison Avenue, 14th Floor New York, NY 10017 212-661-2670 (Name, Address and Telephone Number of Pers |
|
| September 22, 2014 |
diaDexus, Inc. Announces Appointment of Kenneth Fang, M.D., as Chief Medical Officer -Company Also Discloses Departure of Michael Richey as Chief Business Officer- SOUTH SAN FRANCISCO, Calif., Sept. 22, 2014 - diaDexus, Inc. (OTCQB:DDXS), a commercial stage developer of proprietary cardiovascular diagnostic products, today announced that Kenneth C. Fang, M.D. will join the company as chief medical |
|
| September 22, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2014 diaDexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 19, 2014 |
DDXS / Diadexus, Inc. S-8 - - FORM S-8 As filed with the Securities and Exchange Commission on September 19, 2014 Registration No. |
|
| September 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2014 diaDexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 11, 2014 |
diaDexus, Inc. Announces Resignation of Chief Financial Officer Exhibit 99.1 diaDexus, Inc. Announces Resignation of Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Sept. 9, 2014 — diaDexus, Inc. (OTCQB:DDXS), a commercial stage developer of proprietary cardiovascular diagnostic products, today announced that Jean Viret, Ph.D., chief financial officer, will be leaving the company effective September 19, 2014 to pursue an opportunity outside of the company |
|
| September 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2014 diaDexus, Inc. (Exact name of Registrant as specified in its charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Diadexus, Inc. (Name of Issuer) Common Stock, $.01 Par Value (Title of Class of Securities) 25245P 10 6 Cusip Number Norman H. Pessin Brian Pessin 366 Madison Avenue, 14th Floor New York, NY 10017 212-661-2670 (Name, Address and Telephone Number of Person |
|
| August 21, 2014 |
diaDexus, Inc. Secures $15 Million Debt Financing Exhibit 99.1 diaDexus, Inc. Secures $15 Million Debt Financing SOUTH SAN FRANCISCO, Calif., August 18, 2014 — (BUSINESS WIRE) — diaDexus, Inc. (OTCQB: DDXS), a commercial stage developer of proprietary cardiovascular diagnostic products, today announced it has entered into a $15 million senior secured term loan with Oxford Finance. The Company will use the funding to refinance its existing $8.1 mi |
|
| August 21, 2014 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of August 15, 2014 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent |
|
| August 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2014 diaDexus, Inc. |
|
| July 28, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2014 diaDexus, Inc. |
|
| July 28, 2014 |
Exhibit 99.1 diaDexus, Inc. Reports Second Quarter 2014 Financial Results 23 Percent Year-Over-Year Revenue Growth Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the second quarter ended June 30, 2014. "We h |
|
| July 18, 2014 |
diaDexus Announces FDA Acceptance for Review of 510(k) Submission for PLAC Test for Lp-PLA2 Activity EX-99.1 Exhibit 99.1 diaDexus Announces FDA Acceptance for Review of 510(k) Submission for PLAC Test for Lp-PLA2 Activity SOUTH SAN FRANCISCO, Calif., July 17, 2014 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that an administrativ |
|
| July 18, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 d760220d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2014 diaDexus, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 0-26483 94-3236309 (State or Other Jurisdiction of Incorporati |
|
| June 26, 2014 |
EX-99.1 Exhibit 99.1 DIADEXUS ANNOUNCES LEADERSHIP CHANGES TO DRIVE AND SUPPORT FUTURE GROWTH POTENTIAL – Dr. Brian Ward to Retire as CEO by End of 2014 – – Alexander Johnson, formerly of Novartis AG, to Join as President – SOUTH SAN FRANCISCO, Calif.–(June 25, 2014) – diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today annou |
|
| June 26, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2014 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of Incor |
|
| June 2, 2014 |
DIADEXUS, INC. 2012 EQUITY INCENTIVE AWARD PLAN ARTICLE 1 EX-10.1 Exhibit 10.1 DIADEXUS, INC. 2012 EQUITY INCENTIVE AWARD PLAN ARTICLE 1 PURPOSE The purpose of the diaDexus, Inc. 2012 Equity Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of diaDexus, Inc. (the “Company”) by linking the individual interests of the members of the Board, Employees, and Consultants to thos |
|
| June 2, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2014 diaDexus, Inc. |
|
| May 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2014 diaDexus, Inc. |
|
| May 7, 2014 |
EX-99.1 Exhibit 99.1 diaDexus, Inc. Reports First Quarter 2014 Financial Results Increasing Full Year 2014 Revenue Guidance to $27 to $29 Million Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2014 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the first quarte |
|
| May 1, 2014 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2014 diaDexus, Inc. |
|
| May 1, 2014 |
EX-99.1 Exhibit 99.1 diaDexus Announces Completion of Validation Cohort for the PLAC® Test for Lp-PLA2 Activity —On Target to Submit FDA 510(k) Filing Mid-year 2014— —Data from REasons for Geographic And Racial Differences in Stroke (REGARDS), a Large NIH-Funded Longitudinal Observational Study of Stroke and Heart Disease, were Used for Clinical Validation— SOUTH SAN FRANCISCO, Calif. — (May 1, 20 |
|
| April 29, 2014 |
Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2014 diaDexus, Inc. |
|
| April 16, 2014 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 16, 2014 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 10, 2014 |
Exhibit 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Diadexus, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. April 10, 2014 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its general pa |
|
| April 10, 2014 |
DDXS / Diadexus, Inc. / BAKER FELIX - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2014 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 11, 2014 |
10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 11, 2014 |
diaDexus, Inc. SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT Exhibit 10.36 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. diaDexus, Inc. SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this A |
|
| March 11, 2014 |
EX-4.5 Exhibit 4.5 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, |
|
| March 5, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2014 diaDexus, Inc. |
|
| March 5, 2014 |
EX-99.1 Exhibit 99.1 diaDexus, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results 14th Consecutive Quarter of Year-over-Year Revenue Growth Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 5, 2014 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the fo |
|
| March 5, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2014 diaDexus, Inc. |
|
| March 5, 2014 |
EX-99.1 Exhibit 99.1 diaDexus, Inc. Announces Exclusive U.S. Licensing Deal with Thermo Fisher Scientific to Advance Risk Prediction in Heart Failure — Company expands cardiovascular pipeline and aims to address large unmet need for prognosis and risk stratification in patients with heart failure — SOUTH SAN FRANCISCO, Calif.—(March 5, 2014) — diaDexus, Inc. (OTCQB:DDXS), a company developing and |
|
| March 3, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2014 diaDexus, Inc. |
|
| February 14, 2014 |
Exhibit 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Diadexus, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2014 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its general |
|
| February 14, 2014 |
DDXS / Diadexus, Inc. / BAKER FELIX - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 4, 2014 |
DDXS / Diadexus, Inc. / Arthur Greg Gleeson Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DIADEXUS, INC (Name of Issuer) Common Stock (Title of Class of Securities) 25245P106 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| November 12, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2013 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of I |
|
| November 12, 2013 |
EX-99.1 Exhibit 99.1 diaDexus, Inc. Provides Update Related to Topline Lp-PLA2 Inhibitor Data Reported by GlaxoSmithKline —STABILITY Trial Did Not Meet Primary Endpoint; Reduction in Some Secondary Endpoints Observed— —Company Believes PLAC® Test Business Remains Strong— SOUTH SAN FRANCISCO, Calif., November 12, 2013 — diaDexus, Inc. (OTCQB: DDXS), today provided an update to their PLAC® Test busi |
|
| November 7, 2013 |
Amendment No. 2 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* diaDexus, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 52545P106 (CUSIP Number) October 30, 2013 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| November 7, 2013 |
EX-7.1 2 d623196dex71.htm EX-7.1 Exhibit 7.1 JOINT FILING STATEMENT Each of Burrill Life Sciences Capital Fund, L.P. (“BLSCF”); Burrill Indiana Life Sciences Capital Fund, L.P. (“BILSCF”); Burrill & Company (Life Sciences GP), LLC; Burrill & Company (Indiana GP), LLC; and G. Steven Burrill hereby expresses its agreement that the attached Amendment No. 2 to Schedule 13G (and any amendments thereto) |
|
| November 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2013 diaDexus, Inc. |
|
| November 5, 2013 |
DIADEXUS, INC. KEY EMPLOYEE SEVERANCE BENEFIT PLAN EX-10.1 Exhibit 10.1 DIADEXUS, INC. KEY EMPLOYEE SEVERANCE BENEFIT PLAN 1. Introduction. This diaDexus, Inc. Key Employee Severance Benefit Plan (the “Plan”) is established by diaDexus, Inc. (the “Company”) on October 30, 2013 (the “Effective Date”). The Plan provides for severance benefits to selected employees of the Company. This document constitutes the Summary Plan Description for the Plan. 2 |
|
| November 5, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2013 diaDexus, Inc. (Exact name of Registrant as specified in its charter) 0-26483 (Commission File Number) Delaware 94-3236309 (State or Other Jurisdiction of In |
|
| October 29, 2013 |
EX-99.1 Exhibit 99.1 diaDexus, Inc. Reports Third Quarter 2013 Financial Results 13th Consecutive Quarter of Year-over-Year Revenue Growth Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., October 29, 2013 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the third quarter |
|
| October 29, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2013 diaDexus, Inc. |
|
| October 22, 2013 |
diaDexus, Inc. Expands Loan Facility with Comerica to $10 Million EX-99.1 Exhibit 99.1 diaDexus, Inc. Expands Loan Facility with Comerica to $10 Million SOUTH SAN FRANCISCO, Calif., October 22, 2013 — diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it has amended its agreement with Comerica Bank to expand its existing loan facility from $5 million to $10 million. The loan |
|
| October 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2013 diaDexus, Inc. |
|
| October 21, 2013 |
Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2013 diaDexus, Inc. |
|
| August 12, 2013 |
Exhibit 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Diadexus, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. August 12, 2013 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its general p |
|
| August 12, 2013 |
DDXS / Diadexus, Inc. / BAKER FELIX - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 9, 2013 |
DDXS / Diadexus, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 v352508sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* diaDexus, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 25245P106 (CUSIP Number) July 25, 2013 (Date of Event which Requires Filing of this Statement) Check the appropri |
|
| August 8, 2013 |
EX-99.1 2 d580260dex991.htm EX-99.1 Exhibit 99.1 diaDexus, Inc. Reports Second Quarter 2013 Financial Results 12th Consecutive Quarter of Year-over-Year Revenue Growth Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 8, 2013 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial res |
|
| August 8, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2013 diaDexus, Inc. |
|
| August 5, 2013 |
diaDexus, Inc. Appoints Dr. Oye Olukotun to Board of Directors EX-99.1 Exhibit 99.1 diaDexus, Inc. Appoints Dr. Oye Olukotun to Board of Directors SOUTH SAN FRANCISCO, Calif., Aug. 2, 2013 — diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular products, today announced that its Board of Directors has appointed Adeoye (Oye) Y. Olukotun, M.D., M.P.H., F.A.C.C., F.A.H.A. as an independent director. Dr. Olukotun brings |
|
| August 5, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2013 DIADEXUS, INC. |
|
| May 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2013 diaDexus, Inc. |
|
| May 6, 2013 |
EX-99.1 Exhibit 99.1 diaDexus, Inc. Reports First Quarter 2013 Financial Results 11th Consecutive Quarter of Year-over-Year Growth SOUTH SAN FRANCISCO, Calif., May 6, 2013 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the first quarter ended March 31, 2013. Brian Ward, Ph.D., diaDexus’ |
|
| April 29, 2013 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2013 DIADEXUS, INC. |
|
| March 22, 2013 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 7, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2013 DIADEXUS, INC. |
|
| March 7, 2013 |
EX-99.1 Exhibit 99.1 diaDexus, Inc. Reports Fourth Quarter and Full Year 2012 Financial Results 10th Consecutive Quarter of Year-over-Year Growth SOUTH SAN FRANCISCO, Calif., March 7, 2013 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, |
|
| February 8, 2013 |
DDXS / Diadexus, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* diaDexus, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25245P106 (CUSIP Number) January 2, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| November 7, 2012 |
Press Release Exhibit 99.1 diaDexus, Inc. Reports Third Quarter 2012 Financial Results Ninth consecutive quarter of year-over-year revenue growth SOUTH SAN FRANCISCO, Calif., November 07, 2012 — diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the third quarter of 2012. Brian Ward, Ph.D., di |
|
| November 7, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2012 DIADEXUS, INC. |
|
| September 14, 2012 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2012 DIADEXUS, INC. |
|
| September 14, 2012 |
Press Release Exhibit 99.1 diaDexus, Inc. Extends Loan Facility with Comerica Bank Extends Interest-Only Payment Period by 12 months and Lowers Future Principal Payments SOUTH SAN FRANCISCO, Calif., September 13, 2012 — diaDexus, Inc. (OTCQB: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced that it has entered into |
|
| August 28, 2012 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2012 DIADEXUS, INC. |
|
| August 7, 2012 |
Press Release Exhibit 99.1 diaDexus, Inc. Reports Second Quarter 2012 Financial Results Eighth consecutive quarter of year-over-year revenue growth SOUTH SAN FRANCISCO, Calif., August 7, 2012 — diaDexus, Inc. (OTCQB: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced financial results for the second quarter of 2012. |
|
| August 7, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2012 DIADEXUS, INC. |
|
| June 5, 2012 |
DIADEXUS, INC. 2012 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. diaDexus, Inc. 2012 Equity Incentive Award Plan Exhibit 10.1 DIADEXUS, INC. 2012 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the diaDexus, Inc. 2012 Equity Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of diaDexus, Inc. (the “Company”) by linking the individual interests of the members of the |
|
| June 5, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on June 5, 2012 Registration No. |
|
| June 5, 2012 |
DIADEXUS, INC. 2012 EQUITY INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Form of Stock Option Agreement Exhibit 10.2 DIADEXUS, INC. 2012 EQUITY INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE diaDexus, Inc., a Delaware corporation, (the “Company”), pursuant to its 2012 Equity Incentive Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s common |
|
| May 21, 2012 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2012 DIADEXUS, INC. |
|
| May 15, 2012 |
Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2012 DIADEXUS, INC. |
|
| May 8, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2012 DIADEXUS, INC. |
|
| May 8, 2012 |
Press Release Exhibit 99.1 diaDexus, Inc. Reports 2012 First Quarter Financial Results Seven consecutive quarters of revenue growth SOUTH SAN FRANCISCO, Calif., May 8, 2012 — diaDexus, Inc. (OTC Bulletin Board: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced financial results for the first quarter of 2012. Total r |
|
| April 11, 2012 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 22, 2012 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2012 DIADEXUS, INC. |
|
| March 15, 2012 |
Six consecutive quarters of year-over-year revenue growth Press Release Exhibit 99.1 diaDexus, Inc. Reports 2011 Fourth Quarter and Year-End Financial Results Six consecutive quarters of year-over-year revenue growth SOUTH SAN FRANCISCO, Calif., March 15, 2012 – diaDexus, Inc. (OTC Bulletin Board: DDXS.OB), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced financial results for t |
|
| March 15, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2012 DIADEXUS, INC. |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* diaDexus, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25245P106 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 14, 2012 |
DDXS / Diadexus, Inc. / BAKER FELIX - BENEFICIAL OWNERSHIP REPORT Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 18, 2012 |
diaDexus, Inc. Names Jean-Frederic Viret, Ph.D. Chief Financial Officer Press Release Exhibit 99.1 diaDexus, Inc. Names Jean-Frederic Viret, Ph.D. Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Jan. 18, 2012 — diaDexus, Inc. (OTC Bulletin Board: DDXS.OB), a diagnostics company focused on patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced the appointment of Jean-Frederic Viret, Ph.D. as its Chief Financ |
|
| January 18, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2012 DIADEXUS, INC. |
|
| January 9, 2012 |
diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance Press Release Exhibit 99.1 diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance SOUTH SAN FRANCISCO, Calif., Jan. 9, 2012 — diaDexus, Inc. (OTC Bulletin Board: DDXS.OB), a diagnostics company focused on patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced preliminary Q4 2011 revenues of approximately $4.9 million, up 48% from |
|
| January 9, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2012 DIADEXUS, INC. |
|
| October 31, 2011 |
Correspondence October 31, 2011 VIA EDGAR, FEDEX AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 20, 2011 |
Correspondence 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES October 20, 2011 Abu Dhabi Barcelona Beijing Boston Brussels Chicago Doha Dubai Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Moscow Munich New Jersey New York Orange County Paris Riyadh Rome San Diego San Francisco Shanghai Silicon Valley |
